Collection of Venous and Capillary Blood Samples for the Development of New Diagnostic Devices for Cardiovascular Conditions

The purpose of this study is for the development of innovative state of the art diagnostic devices that radically enhance clinicians and patients ability to monitor and manage chronic health conditions which improve outcomes and reduce the cost of care for large numbers of people. LumiraDx are developing a range of biomarkers which cover cardiovascular health, kidney failure, liver disease, thromboembolic events and inflammation.
Samples will be used to develop new products and platforms for measuring biomarkers including, but not limited to Troponin, NT-pro BNP, BNP, CK-MB, D-Dimer, NGAL, Cystatin C, Myoglobin, Galectin-3, CRP, AST, ALT, Lipids, Coagulation.

Status: active

Start Date

April 2019

Coordinated by

Nicola Freeman

Main Trial Site

Royal Infirmary Edinburgh and St John's Hospital